Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma.
Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Charissa WijnandsLaboratory Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Peter G A KarelLaboratory of Clinical Chemistry, Deventer Ziekenhuis, 7416 SE Deventer, The Netherlands.ORCID 0000-0002-3770-8702
Jolein GloerichTranslational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0001-5976-8426
Gad ArmonyTranslational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-6503-9673
Anastasia TzastaLaboratory Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Corrie M de Kat AngelinoLaboratory Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Theo M LuiderDepartment of Neurology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Martijn M VanDuijnDepartment of Neurology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-6654-994X
Sandra J CroockewitDepartment of Hematology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0003-3101-1194
Elizabeth A de KortDepartment of Hematology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0003-0125-9543
Daan A R CastelijnDepartment of Hematology, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands.
Claudia A M StegeDepartment of Hematology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-7476-0609
Hans J C T WesselsTranslational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Alain J van GoolTranslational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0003-0010-5286
Niels W C J van de DonkDepartment of Hematology, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-7445-2603
Joannes F M JacobsLaboratory Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-6208-6386
Funding
Dutch Cancer Society 14465EnFORCE (PPP Allowance made available by Health~Holland) LSHM21032PRIMETIME (PPP Allowance made available by Health~Holland) xSebia xThe Netherlands X-omics Initiative, which is (partially) funded by the Dutch Research Council 184.034.019
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
bispecific antibodyminimal residual diseasemultiple myelomatherapeutic antibodytherapeutic drug monitoringtherapy response kinetics
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma. · full record | OpenQuestion